Clinical Trials Browser

Phase 1/2 × Melanoma × navitoclax × Clear all

NCT01989585 2026-05-13

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Phase 1/2 Active not recruiting

Melanoma